Last reviewed · How we verify
Cellcept® in autoimmune bullous dermatoses
Cellcept (mycophenolate mofetil) selectively inhibits inosine monophosphate dehydrogenase (IMPDH) in T and B lymphocytes, suppressing their proliferation and reducing autoimmune responses.
Cellcept (mycophenolate mofetil) selectively inhibits inosine monophosphate dehydrogenase (IMPDH) in T and B lymphocytes, suppressing their proliferation and reducing autoimmune responses. Used for Autoimmune bullous dermatoses (including pemphigus vulgaris, bullous pemphigoid, and related conditions).
At a glance
| Generic name | Cellcept® in autoimmune bullous dermatoses |
|---|---|
| Sponsor | University Hospital, Limoges |
| Drug class | Immunosuppressant; inosine monophosphate dehydrogenase (IMPDH) inhibitor |
| Target | IMPDH type II (inosine monophosphate dehydrogenase type II) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Dermatology |
| Phase | Phase 3 |
Mechanism of action
Mycophenolate mofetil is an immunosuppressant that preferentially targets IMPDH type II, which is predominantly expressed in activated lymphocytes. By depleting guanosine nucleotides required for DNA synthesis, it suppresses T and B cell proliferation without affecting other cell types as severely. In autoimmune bullous dermatoses, this reduces the pathogenic autoantibody production and T cell-mediated inflammation driving blister formation.
Approved indications
- Autoimmune bullous dermatoses (including pemphigus vulgaris, bullous pemphigoid, and related conditions)
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, abdominal pain)
- Leukopenia
- Infection (due to immunosuppression)
- Anemia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: